Literature DB >> 35714734

Retinopathy of Prematurity Treatment Trends from 2003 to 2020 in the United States.

Suleman I Khan1, Won Yeol Ryu2, Edward H Wood1, Darius M Moshfeghi1, Jennifer Krupa Shah1, Scott R Lambert3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35714734      PMCID： PMC9509438          DOI： 10.1016/j.ophtha.2022.06.008

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   14.277


× No keyword cloud information.
  7 in total

1.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

2.  The Epidemiology of Retinopathy of Prematurity in the United States.

Authors:  Cassie A Ludwig; Tiffany A Chen; Tina Hernandez-Boussard; Andrew A Moshfeghi; Darius M Moshfeghi
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2017-07-01       Impact factor: 1.300

3.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004

4.  Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database.

Authors:  Michael H Zhang; Michael P Blair; Sandra A Ham; Sarah H Rodriguez
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2020-09-01       Impact factor: 1.300

5.  Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Antonio Baldascino; Lorenzo Orazi; Maria Sammartino; Velia Purcaro; Carmen Giannantonio; Patrizia Papacci; Costantino Romagnoli
Journal:  Ophthalmology       Date:  2014-07-04       Impact factor: 12.079

6.  Trends in Retinopathy of Prematurity Screening and Treatment: 2008-2018.

Authors:  S Grace Prakalapakorn; Lucy Greenberg; Erika M Edwards; Danielle E Y Ehret
Journal:  Pediatrics       Date:  2021-05-11       Impact factor: 7.124

7.  Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.

Authors:  Andreas Stahl; Domenico Lepore; Alistair Fielder; Brian Fleck; James D Reynolds; Michael F Chiang; Jun Li; Melissa Liew; Rainer Maier; Qi Zhu; Neil Marlow
Journal:  Lancet       Date:  2019-09-12       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.